10-Q: Plexus Corp. Reports Strong Q3 Fiscal 2025 Earnings with Significant Profit Growth and Margin Expansion

Plexus Corp. announced a substantial increase in net income and diluted earnings per share for the third quarter and first nine months of fiscal 2025, driven by improved operational efficiencies and reduced restructuring charges.

Summary

• Net sales for the three months ended June 28, 2025, increased by 6.0% to $1,018.3 million, up from $960.8 million in the prior year period.
• Net sales for the nine months ended June 28, 2025, increased by 2.2% to $2,974.6 million, compared to $2,910.3 million in the previous year.
• Gross profit for the three months rose 9.4% to $103.3 million, with gross margin expanding by 30 basis points to 10.1%.
• Gross profit for the nine months increased 11.5% to $301.7 million, with gross margin improving by 80 basis points to 10.1%.
• Operating income for the three months surged 36.7% to $53.6 million, and operating margin increased by 120 basis points to 5.3%.
• Operating income for the nine months grew 31.1% to $149.3 million, with operating margin rising by 110 basis points to 5.0%.
• Net income for the three months ended June 28, 2025, increased by 79.7% to $45.1 million, up from $25.1 million.
• Net income for the nine months ended June 28, 2025, increased by 72.1% to $121.5 million, up from $70.6 million.
• Diluted earnings per share for the three months increased to $1.64 from $0.91.
• Diluted earnings per share for the nine months increased to $4.39 from $2.53.
• Return on Invested Capital (ROIC) for the nine months improved to 14.1% from 10.4% in the prior year, resulting in an economic return of 5.2% (vs. 2.2%).
• Cash and cash equivalents decreased to $237.6 million as of June 28, 2025, from $347.5 million as of September 28, 2024.
• Total debt, finance lease, and other financing obligations significantly decreased to $143 million as of June 28, 2025, from $247.3 million as of September 28, 2024.
• Cash flows provided by operating activities for the nine months decreased to $117.2 million from $216.4 million, primarily due to changes in working capital.
• Free Cash Flow (FCF) for the nine months decreased to $56.8 million from $147.5 million.
• Annualized cash cycle days improved by 14 days, decreasing to 69 days as of June 28, 2025, from 83 days in the prior year.
• The APAC segment saw net sales increase by 13.9% for the three months and 12.0% for the nine months, driven by increased customer end-market demand and new product ramps.
• The Healthcare/Life Sciences sector experienced a 10.6% increase in net sales for the three months and a 5.8% increase for the nine months, primarily due to production ramps of new products.
• Restructuring and other charges decreased significantly, with no charges incurred in the three months ended June 28, 2025, compared to $9.2 million in the prior year period.

Sentiment

Score: 8

Explanation: The company reported exceptionally strong net income and EPS growth, significant margin expansion, improved ROIC, and reduced debt. While operating cash flow decreased due to working capital changes, the overall financial health and efficiency metrics are very positive, indicating strong performance and effective management.

Positives

• Net income increased by 79.7% for the three months and 72.1% for the nine months, demonstrating strong profitability growth.
• Diluted EPS saw substantial increases, rising to $1.64 for the quarter and $4.39 for the nine-month period.
• Gross margin expanded by 30 basis points for the quarter and 80 basis points for the nine months, indicating improved operational efficiency.
• Operating margin increased by 120 basis points for the quarter and 110 basis points for the nine months, reflecting better cost management.
• Return on Invested Capital (ROIC) improved to 14.1% for the nine months, exceeding the Weighted Average Cost of Capital (WACC) by 5.2%, indicating strong value creation.
• Total debt and financing obligations decreased significantly from $247.3 million to $143 million, strengthening the balance sheet.
• Cash cycle days improved by 14 days, driven by inventory reduction efforts and improved materials management.
• The APAC segment and Healthcare/Life Sciences sector showed robust sales growth due to increased demand and new product ramps.
• Restructuring and other charges were significantly lower in the current quarter and nine-month period compared to the prior year, contributing to higher operating income.

Negatives

• Cash and cash equivalents decreased by $109.9 million from September 28, 2024, to June 28, 2025.
• Cash flows provided by operating activities for the nine months decreased by $99.2 million compared to the prior year, primarily due to working capital changes.
• Free Cash Flow (FCF) for the nine months decreased by $90.7 million compared to the prior year.
• Net sales in the EMEA segment decreased by 14.3% for the three months and 21.7% for the nine months, primarily due to decreased customer end-market demand.
• The AMER segment experienced a 3.5% decrease in net sales for the nine months, driven by decreased customer end-market demand, customer disengagements, and program discontinuation.

Risks

• Effects of tariffs, trade disputes, trade agreements, and other trade protection measures.
• Impact of inflationary pressures on production costs, profitability, and market economic outlook.
• Shortages and delays in obtaining components due to economic cycles, natural disasters, or other factors.
• Customer delays, changes, cancellations, or forecast inaccuracies in both ongoing and new programs.
• Ability to realize anticipated savings from restructuring or similar actions, and adequacy of related charges.
• Lack of visibility of future orders, especially with changing economic conditions.
• Economic performance of the industries, sectors, and customers served.
• Outcome of litigation and regulatory investigations and proceedings.
• Effects of revenue volume from certain sectors or programs on margins in particular periods.
• Ability to secure new customers, maintain current customer base, and deliver product on a timely basis.
• Risks of concentration of work for certain customers.
• Particular risks related to new or recent customers, programs, or services, including start-up costs and execution challenges.
• Effects of start-up costs of new programs and facilities or costs associated with facility closure/consolidation.
• Possible unexpected costs and operating disruption during program transitions.
• Risk that new program wins and/or customer demand may not result in expected revenue or profitability.
• Customer orders may not lead to long-term relationships.
• Ability to successfully manage and execute a complex business model with high product mix and demanding requirements.
• Risks associated with excess and obsolete inventory, including customer non-payment for purchased inventory.
• Risks related to information technology systems and data security.
• Increasing regulatory and compliance requirements.
• Any tax law changes and related foreign jurisdiction tax developments.
• Current or potential future barriers to the repatriation of funds held outside of the United States.
• Potential effects of jurisdictional results on taxes, tax rates, and ability to use deferred tax assets and net operating losses.
• Weakness in areas of the global economy.
• Effect of changes in the pricing and margins of products.
• Raw materials and component cost fluctuations.
• Potential effect of fluctuations in the value of currencies in which business is transacted.
• Effects of changes in economic, political, and regulatory matters in the United States and other countries.
• Potential effect of other world or local events or events outside control (e.g., conflicts, energy prices, terrorism, health epidemics, weather events).
• Impact of increased competition.
• Inability to successfully manage human capital.
• Changes in financial accounting standards.

Future Outlook

The company expects its annual effective tax rate for fiscal 2025 to be approximately 10.0% to 12.0%, assuming no changes to tax laws. Capital expenditures for fiscal 2025 are estimated to be between $80.0 million and $100.0 million to support new program ramps and replace older equipment. The company believes its projected cash flows from operations, available cash, potential borrowings under the Credit Facility, and leasing capabilities will be sufficient to meet working capital and fixed capital requirements, as well as execute share repurchase authorizations, for the next twelve months. The company is evaluating the impact of the recently enacted One Big Beautiful Bill Act on its consolidated financial statements.

Management Comments

• We believe that our projected cash flows provided by operations, available cash and cash equivalents, potential borrowings under the Credit Facility, and our leasing capabilities should be sufficient to meet our working capital and fixed capital requirements, as well as execute our share repurchase authorization as management deems appropriate, for the next twelve months.
• Our balance sheet is positioned to support the potential future challenges presented by macroeconomic factors including increased working capital requirements associated with longer lead-times for components, increased component and labor costs, and operating inefficiencies due to supply chain constraints.

Industry Context

Plexus Corp. operates in the Electronics Manufacturing Services (EMS) industry, providing design, manufacturing, and service solutions for highly complex products. The company serves demanding regulatory environments across Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The strong performance in Healthcare/Life Sciences and APAC suggests robust demand in these areas, potentially indicating resilience or growth in medical device and Asian manufacturing markets. The decline in EMEA sales and some AMER segments may reflect regional economic softness or specific customer disengagements, contrasting with the overall positive industry trends for advanced technology manufacturing.

Comparison to Industry Standards

• The company's ROIC of 14.1% for the nine months ended June 28, 2025, significantly exceeds its Weighted Average Cost of Capital (WACC) of 8.9%, indicating strong value creation relative to its cost of capital. This performance is a key internal benchmark for management decisions and compensation.
• The filing does not provide specific comparable companies, projects, or industry benchmarks for a direct external comparison of financial results or operational metrics.

Corporate Governance

Legal Proceedings

• The company is party to lawsuits in the ordinary course of business and records provisions for pending legal matters when an unfavorable outcome is probable and estimable. Management does not believe any such proceedings will have a material positive or adverse effect on the company's consolidated financial position, results of operations, or cash flows.

Stakeholder Impact

• **Shareholders:** Positive impact due to significant increases in net income and diluted EPS, improved ROIC, and ongoing share repurchase programs, which enhance shareholder value.
• **Employees:** Restructuring activities in EMEA and AMER regions involved workforce reductions, impacting some employees through severance costs.
• **Customers:** Continued focus on new product ramps and increased end-market demand, particularly in Healthcare/Life Sciences and APAC, suggests strong customer relationships and product delivery.
• **Suppliers:** Changes in accounts payable and inventory levels indicate shifts in materials procurement and payments to suppliers, potentially affecting supplier relationships and cash flow dynamics.
• **Creditors:** Reduced debt and finance lease obligations demonstrate improved financial stability and lower leverage, benefiting creditors.

Next Steps

• Evaluate the impact of the One Big Beautiful Bill Act on consolidated financial statements.
• Continue to execute the $100.0 million 2026 share repurchase program, which became effective upon completion of the 2025 Program.
• Adopt ASU 2023-07 Segment Reporting retrospectively in the fourth quarter of fiscal 2025.
• Adopt ASU 2023-09 Income Taxes prospectively in the first quarter of fiscal 2026.
• Continue to make cash payments for U.S. federal taxes on deemed repatriation of undistributed foreign earnings through fiscal 2026.
• Invest approximately $80.0 million to $100.0 million in capital expenditures for fiscal 2025 to support new program ramps and replace older equipment.

Key Dates

Recommendation

The company delivered exceptionally strong financial results, with significant increases in net income, diluted EPS, and expanded gross and operating margins. The improvement in Return on Invested Capital (ROIC) and the reduction in overall debt demonstrate effective capital management and a strengthening balance sheet. While operating cash flow saw a decrease, it was primarily attributed to working capital adjustments, including inventory reduction, which is a positive sign of efficiency. The approval of a new $100 million share repurchase program further signals management's confidence and commitment to shareholder returns. These factors collectively point to a robust financial position and positive operational momentum, making the stock an attractive investment.

Keywords

Electronics Manufacturing Services, EMS, Contract Manufacturing, Aerospace Defense, Healthcare Life Sciences, Industrial, Supply Chain, Global Manufacturing, SEC Filing, 10-Q, Financial Results, Profitability, Revenue, Earnings Per Share, Share Repurchase, Debt Management, Working Capital, Cash Flow, Operational Efficiency